GREENWOOD VILLAGE, Colo.,
April 1, 2011 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE) ("Ampio")
announced today that Mark D.
McGregor will be appointed to the position of Chief
Financial Officer and Corporate Secretary effective April 4, 2011. Mr. Bruce
G. Miller, who served in these capacities since April 2010, will be joining the team that will
advance the commercialization of Zertane, Ampio's product candidate
that was the subject of a 2009 and 2010 Phase 3 multicenter
clinical trial in Europe and was
obtained through our acquisition of DMI BioSciences, Inc. Mr.
Miller was with DMI BioSciences since 1992, having served as Chief
Executive Officer and/or President throughout this period.
Mr. McGregor, a Certified Public Accountant, is a highly
experienced financial executive with in-depth experience in
treasury and risk management, including developing financial
strategic plans, cash management and investments, managing foreign
currency and interest rate exposures, credit provider and credit
rating agency relations, and insurance risk management. His prior
experience also encompasses:
- corporate and international consolidation and reporting,
- SEC and management reporting,
- financial integration,
- disbursements operations,
- evaluating potential acquisitions,
- conducting financial due diligence,
- negotiating credit line provisions to promote operating
flexibility,
- optimizing capital structures, and
- implementing stock buy-back programs to enhance stockholder
value.
Mr. McGregor's career spans over 30 years of financial
experience in a variety of industries. For 20 years he was with
Storage Technology Corporation, a public international information
and storage technology company with $2
billion in annual worldwide revenues, where he served in a
variety of financial positions and advanced to Vice President,
Corporate Treasurer and Corporate Development. Mr. McGregor was
directly involved in two divestitures and four acquisitions while
with Storage Technology Corporation, in addition to leading the
deal team in connection with the sale of StorageTek to Sun
Microsystems in 2005. He began his career with Price Waterhouse,
now PricewaterhouseCoopers LLP, where he spent 13 years with the
Audit Department.
About Ampio
Ampio Pharmaceuticals, Inc. develops innovative proprietary
drugs for metabolic disease, eye disease, kidney disease,
inflammation, CNS disease, and male sexual dysfunction. The product
pipeline includes new uses for previously approved drugs and new
molecular entities ("NMEs"). By concentrating on development of new
uses for previously approved drugs, approval timelines, costs and
risk of clinical failure are reduced because these drugs have
strong potential to be safe and effective while their shorter
development times can significantly increase near-term value. A key
strategy includes actively exploring partnership, licensing and
other collaboration opportunities to maximize Ampio's product
development programs.
Forward-Looking Statements
Except for the historical information contained herein, this
news release contains forward-looking statements that involve risk
and uncertainties. The risks and uncertainties are detailed from
time to time in Ampio's filings with the Securities and Exchange
Commission, including Ampio's Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q.
Contact: Investor Relations
Ampio Pharmaceuticals, Inc: 303-418-1000
Redwood Consultants, LLC : 415-884-0348
SOURCE Ampio Pharmaceuticals, Inc.